Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 761 across all filing types
Latest filing 2019-10-14 Regulatory Filings
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Karolinska Development’s portfolio company OssDsign receives US FDA clearance for Cranial PSI Accessories
Regulatory Filings Classification · 1% confidence The document is a short press release from Karolinska Development announcing that its portfolio company, OssDsign AB, received 510(k) clearance from the US FDA for a medical device accessory. It contains key highlights, contact information, and an 'Attachment' link. Given the short length (3391 characters) and the nature of the announcement (a regulatory milestone update rather than a comprehensive financial report or a formal regulatory filing like a 10-K or IR), it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a specific reporting period, but since it's a specific operational/regulatory update, RNS is the most appropriate general category for non-standard announcements. However, since it is an announcement of a specific regulatory event (FDA clearance), and not a general regulatory filing fallback, I must check if any other category fits better. None of the specific categories (like LTR for legal proceedings, or ER for earnings) fit perfectly. Therefore, RNS (Regulatory Filings - general regulatory announcements and fallback) is the most suitable classification for this type of press release detailing a specific regulatory achievement.
2019-10-14 English
Karolinska Development’s portfolio company Aprea Therapeutics Announces Closing of Initial Public Offering
Share Issue/Capital Change Classification · 1% confidence The document is a press release from Karolinska Development AB announcing that its portfolio company, Aprea Therapeutics, Inc., has closed its Initial Public Offering (IPO) and detailing the gross proceeds received. This event—the completion of a public offering and the resulting capital structure change for the portfolio company—falls under financing activities. While it relates to an IPO, the core subject is the successful completion of fundraising/capital raising for an associated entity, which aligns best with the 'Capital/Financing Update' category (CAP). It is not a formal regulatory filing like a 10-K or IR, nor is it a general earnings release or management discussion. The document is short and announces a specific financial transaction.
2019-10-08 English
Karolinska Developments portföljbolag Aprea Therapeutics har fastställt priset i sin börsnotering
Capital/Financing Update Classification · 1% confidence The document is a press release from Karolinska Development AB announcing the pricing of an IPO for its portfolio company, Aprea Therapeutics. It details the financial impact on the company's holdings and provides context on the portfolio company's business. While it mentions a link to a document, the text itself is a standard corporate announcement regarding a capital/financing event (the IPO of a portfolio company). Given the specific nature of the announcement regarding financing and capital structure changes, it fits best under the Capital/Financing Update category.
2019-10-03 Swedish
Karolinska Development’s portfolio company Aprea Therapeutics has priced its initial public offering
Regulatory Filings Classification · 1% confidence The document is a press release from Karolinska Development AB announcing that its portfolio company, Aprea Therapeutics, has priced its Initial Public Offering (IPO) of common stock. This announcement details the offering price, expected trading date, and the resulting valuation change for Karolinska Development. An IPO pricing announcement, which involves the issuance of new shares and capital structure changes for the subsidiary, is best classified as a Capital/Financing Update (CAP). Although it relates to share issuance, the primary focus is the financing event (the IPO) rather than a direct share repurchase or capital change by the reporting entity itself, making CAP more appropriate than SHA or POS. It is not a full financial report (10-K, IR) or a general regulatory filing (RNS), as it fits the specific 'CAP' definition.
2019-10-03 English
Karolinska Development’s portfolio company Aprea Therapeutics has priced its initial public offering
Share Issue/Capital Change Classification · 1% confidence The document is a press release from Karolinska Development AB announcing that its portfolio company, Aprea Therapeutics, has priced its Initial Public Offering (IPO) of common stock. This event involves fundraising, capital structure changes (going public), and the sale of securities. Reviewing the definitions, the most appropriate category is 'Capital/Financing Update' (CAP), as an IPO is a primary financing activity. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). Since it is an announcement about a financing event, CAP is the best fit.
2019-10-03 English
Karolinska Developments portföljbolag Aprea Therapeutics har fastställt priset i sin börsnotering
Share Issue/Capital Change Classification · 1% confidence The document is a press release from Karolinska Development AB announcing that its portfolio company, Aprea Therapeutics, has priced its Initial Public Offering (IPO) in the USA, including the number of shares and the price per share. This announcement details a significant financing/capital structure event (an IPO) involving the company's assets/subsidiaries. This clearly falls under the definition of 'Capital/Financing Update' (CAP). The document is short (4102 characters) and functions as an announcement, but the core subject matter is the financing event itself, not just the announcement of a report, making CAP a more specific fit than RPA or RNS.
2019-10-03 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.